Search
Adaptive Biotechnologies Corp
ADPTAdd to Watchlist
17.530USD
+0.750+4.47%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
2.81BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Adaptive Biotechnologies Corp is 8.50, ranking 106 out of 389 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 21.00 and a low of 18.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
20.333
Target Price
+15.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Adaptive Biotechnologies Corp
ADPT
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Adaptive Biotechnologies Corp's expected revenue for the next quarter?
Adaptive Biotechnologies Corp's expected revenue is 66.10M.
What is Adaptive Biotechnologies Corp's price target?
Analysts forecast that Adaptive Biotechnologies Corp's price target is USD 20.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 18.00.
How have Adaptive Biotechnologies CorpADPT's recent earnings per share performed?
The market expectation was USD -0.13, while Adaptive Biotechnologies CorpADPT's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD -0.13.
What is the analyst rating for Adaptive Biotechnologies Corp?
Based on the ratings of Adaptive Biotechnologies Corp's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
